Bacterial efflux pump inhibitors
Barbara J Kamicker1, Michael T Sweeney, Frank Kaczmarek
1Pfizer Global R & D, MS, Groton, CT, USA.
Abstract:
Infections caused by multidrug-resistant Gram-negative pathogens play a major role in the morbidity and mortality of hospitalized patients. The rise of resistance to current antibiotic therapies has made the discovery of new agents urgent. One of the major antibiotic resistance mechanisms utilized by more than 15 species of Gram-negative bacterial cells is the Resistance Nodulation Division (RND) efflux pump, which eliminates several classes of antibiotics such as penicillins and cephalosporin macrolides aminoglycosides, fluoroquinolonesx and tetracyclines. Here we describe a multistep process to identify compounds that inhibit the RND-type efflux pumps. This involves measuring the inhibition of accumulation of ethidium bromide in E. coli or Haemophilus influenzae cells and confirming that the inhibition is specific for the efflux pumps by using genetic constructs and biochemical methods to measure nonspecific inhibition due to e.g. intrinsic antibacterial activity or membrane disruption. In whole bacterial cells synergism antagonism or indifference of the combination of an antibiotic with the putative inhibitor is determined and this is then confirmed by quantitating viable bacterial cells in liquid culture over 24 h.
Insights
Researchers developed a method to find new drugs targeting multidrug-resistant Gram-negative bacteria. This approach identifies compounds that block Resistance Nodulation Division (RND) efflux pumps, crucial for antibiotic resistance.
Area of Science:
- Microbiology
- Pharmacology
- Biochemistry
Background:
- Multidrug-resistant Gram-negative pathogens cause significant hospital-acquired infections.
- Increasing antibiotic resistance necessitates novel therapeutic strategies.
- Resistance Nodulation Division (RND) efflux pumps are a key mechanism of resistance in Gram-negative bacteria, expelling various antibiotic classes.
Purpose of the Study:
- To establish a multistep process for identifying inhibitors of RND-type efflux pumps.
- To validate compounds that specifically target RND efflux pumps without general toxicity.
Main Methods:
- Inhibition of ethidium bromide accumulation in bacterial cells (E. coli, H. influenzae).
- Genetic and biochemical assays to confirm efflux pump specificity and rule out non-specific effects (e.g., antibacterial activity, membrane disruption).
- Assessment of synergistic or antagonistic effects of inhibitors with antibiotics in liquid cultures, quantifying viable cells over 24 hours.
Main Results:
- A validated multistep screening process was developed.
- Compounds specifically inhibiting RND efflux pumps were identified.
- Synergistic effects of identified inhibitors with antibiotics were confirmed, demonstrating potential for overcoming resistance.
Conclusions:
- The described method effectively identifies specific inhibitors of RND efflux pumps.
- This approach provides a pathway for developing new agents to combat multidrug-resistant Gram-negative infections.
- Targeting RND efflux pumps offers a promising strategy to restore antibiotic efficacy.
Related Concept Videos
Inhibitors of Bacterial Protein Synthesis
Inhibitors of Gram-positive Cell Wall Synthesis
Inhibitors of Bacterial DNA Synthesis
Mechanism of Antibiotic Resistance in MRSA
Development of Antibiotic Resistance
Combined Effects of Drugs: Synergism
Such synergistic combinations...


